Total Payments
$819,400
2024 Payments
$174,674
Companies
39
Transactions
1,568
Medicare Patients
7,251
Medicare Billing
$2.3M
Payment Breakdown by Category
Other$642,045 (78.4%)
Travel$142,572 (17.4%)
Food & Beverage$30,744 (3.8%)
Consulting$3,025 (0.4%)
Education$1,014 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $424,407 | 272 | 51.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $217,638 | 115 | 26.6% |
| Travel and Lodging | $142,572 | 296 | 17.4% |
| Food and Beverage | $30,744 | 842 | 3.8% |
| Consulting Fee | $3,025 | 2 | 0.4% |
| Education | $1,014 | 41 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $476,094 | 589 | $0 (2023) |
| Amgen Inc. | $99,313 | 155 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $98,387 | 134 | $0 (2024) |
| ANI Pharmaceuticals, Inc. | $39,878 | 92 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $37,772 | 107 | $0 (2024) |
| Travere Therapeutics, Inc. | $29,061 | 47 | $0 (2024) |
| Horizon Pharma plc | $12,034 | 22 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $9,936 | 69 | $0 (2024) |
| Vifor Pharma, Inc. | $6,539 | 30 | $0 (2024) |
| Relypsa, Inc. | $2,202 | 25 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $174,674 | 318 | Amgen Inc. ($98,326) |
| 2023 | $170,888 | 328 | Horizon Therapeutics plc ($87,103) |
| 2022 | $192,861 | 292 | Horizon Therapeutics plc ($134,388) |
| 2021 | $127,134 | 239 | Horizon Therapeutics plc ($118,672) |
| 2020 | $45,143 | 108 | Horizon Therapeutics plc ($42,617) |
| 2019 | $94,210 | 167 | Horizon Therapeutics plc ($93,315) |
| 2018 | $12,987 | 67 | Horizon Pharma plc ($11,913) |
| 2017 | $1,503 | 49 | Mallinckrodt LLC ($428.14) |
All Payment Transactions
1,568 individual payment records from CMS Open Payments — Page 1 of 63
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/27/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $180.00 | General |
| 12/22/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/20/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Honoraria | Cash or cash equivalent | $2,700.00 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $1,109.78 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Travel and Lodging | In-kind items and services | $60.00 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $79.22 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,255.00 | General |
| Category: Cardio-renal | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,127.50 | General |
| Category: Cardio-renal | ||||||
| 12/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $907.50 | General |
| Category: Cardio-renal | ||||||
| 12/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $149.79 | General |
| Category: Cardio-renal | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $34.10 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $8.29 | General |
| Category: Cardio-renal | ||||||
| 12/04/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Hyperkalemia | ||||||
| 12/02/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 12/02/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $19.53 | General |
| Category: NEPHROLOGY | ||||||
| 12/02/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $10.78 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/02/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $1.38 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,255.00 | General |
| Category: Cardio-renal | ||||||
| 11/26/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $94.91 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/25/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/23/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Travel and Lodging | In-kind items and services | $1,108.48 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/22/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $90.94 | General |
| Category: LUPUS NEPHRITIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,807 | 3,731 | $3.2M | $1.3M |
| 2022 | 16 | 1,589 | 2,717 | $721,671 | $313,478 |
| 2021 | 15 | 1,859 | 3,395 | $836,381 | $363,173 |
| 2020 | 16 | 1,996 | 3,513 | $941,512 | $361,359 |
Total Patients
7,251
Total Services
13,356
Medicare Billing
$2.3M
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2507 | Injection, pegloticase, 1 mg | Office | 2023 | 12 | 416 | $2.3M | $914,171 | 39.2% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 183 | 327 | $201,517 | $96,411 | 47.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 350 | 854 | $185,216 | $86,160 | 46.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 218 | 442 | $102,615 | $47,275 | 46.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 200 | 217 | $91,658 | $31,934 | 34.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 210 | 378 | $57,191 | $25,383 | 44.4% |
| 90937 | Hemodialysis procedure requiring repeated evaluation | Facility | 2023 | 136 | 295 | $76,700 | $25,261 | 32.9% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 31 | 54 | $27,593 | $13,241 | 48.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 139 | 188 | $29,531 | $13,021 | 44.1% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 48 | 50 | $25,175 | $12,014 | 47.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 53 | 53 | $18,830 | $7,310 | 38.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 55 | 60 | $17,300 | $6,644 | 38.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 12 | 52 | $15,284 | $5,983 | 39.1% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 63 | 91 | $18,200 | $5,444 | 29.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 21 | 21 | $7,350 | $4,831 | 65.7% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 26 | 26 | $7,800 | $4,440 | 56.9% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 14 | 37 | $9,250 | $2,675 | 28.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 56 | $3,515 | $1,377 | 39.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 12 | 62 | $2,128 | $835.04 | 39.2% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 12 | 52 | $574.32 | $219.86 | 38.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 191 | 305 | $187,959 | $94,898 | 50.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 338 | 803 | $121,559 | $48,728 | 40.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 153 | 272 | $62,995 | $28,280 | 44.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 166 | 354 | $70,800 | $21,890 | 30.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 168 | 242 | $52,485 | $21,062 | 40.1% |
About Dr. Payam Shakouri, M.D
Dr. Payam Shakouri, M.D is a Nephrology healthcare provider based in Poughkeepsie, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2013. The National Provider Identifier (NPI) number assigned to this provider is 1184963746.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Payam Shakouri, M.D has received a total of $819,400 in payments from pharmaceutical and medical device companies, with $174,674 received in 2024. These payments were reported across 1,568 transactions from 39 companies. The most common payment nature is "Honoraria" ($424,407).
As a Medicare-enrolled provider, Shakouri has provided services to 7,251 Medicare beneficiaries, totaling 13,356 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Internal Medicine
- Location Poughkeepsie, NY
- Active Since 02/01/2013
- Last Updated 05/08/2017
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1184963746
Products in Payments
- KRYSTEXXA (Biological) $569,245
- Kerendia (Drug) $94,055
- PURIFIED CORTROPHIN GEL (Drug) $40,115
- LUPKYNIS (Drug) $37,772
- KRYSTEXXA (Drug) $12,034
- FARXIGA (Drug) $9,234
- Veltassa (Drug) $8,741
- ACTHAR (Biological) $1,724
- LOKELMA (Drug) $595.24
- TARPEYO (Drug) $433.83
- RAYALDEE (Drug) $358.69
- Parsabiv (Biological) $344.01
- JYNARQUE (Drug) $331.52
- SOLIRIS (Drug) $310.39
- JARDIANCE (Drug) $292.13
- Velphoro (Drug) $289.94
- Ozempic (Drug) $224.74
- BENLYSTA (Biological) $215.63
- Parsabiv (Drug) $206.18
- GATTEX (Drug) $169.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.